The gut-brain axis in Alzheimer's and Parkinson's diseases: a systematic review of microbiota-derived biomarkers and novel therapeutic approaches - PubMed
3 hours ago
- #gut-brain axis
- #neurodegenerative diseases
- #microbiome biomarkers
- Gut microbiota changes significantly influence Alzheimer's disease (AD) and Parkinson's disease (PD) onset and progression.
- Short-chain fatty acids (SCFAs) like butyrate and acetate serve as noninvasive biomarkers for AD, mild cognitive impairment, and PD, with lower levels linked to cognitive decline.
- Combining SCFAs improves diagnostic accuracy, showing AUCs from 0.75 to 0.87.
- Trimethylamine N-oxide (TMAO) levels have inconsistent associations with disease risk, with both increases and decreases reported.
- Therapies targeting gut microbiota, such as probiotics, prebiotics, diet changes, and fecal microbiota transplantation, show cognitive benefits and modulate gut-brain signaling.
- Gut-derived biomarkers hold promise for early diagnosis and new treatments in AD and PD, though evidence for other neurodegenerative diseases is limited.